U.S. Vaccines Market By Technology Type , By Indication By End User : Opportunity Analysis and Industry Forecast, 2024-2033

Description

The U.S. vaccines market was valued at $16.4 billion in 2023, and is projected to reach $29.1 billion by 2033, growing at a CAGR of 5.9% from 2024 to 2033.

Vaccine is a biological preparation that provides acquired immunity to a particular infectious disease. It contains antigens, which are weakened or inactivated forms of the pathogen, or pieces of the pathogen such as proteins or sugars. When administered, vaccines stimulate the body's immune system to recognize and fight the targeted pathogen, preparing it for future encounters. This proactive approach helps prevent the onset of diseases that can cause significant morbidity and mortality.

Alarming increase in prevalence of infectious diseases, including seasonal flu, influenza, shingles, and pneumonia, has spurred demand for vaccines to prevent outbreaks and mitigate public health risks. According to the Centers for Disease Control and Prevention, seasonal flu infections in the U.S. lead to an average of 140,000 to 710,000 hospitalizations annually, which drives the demand for annual flu vaccines. In addition, U.S. government initiatives, such as the Vaccines for Children program, which provides vaccines at no cost to eligible children, and adult immunization programs, promote access to vaccines, ensuring higher vaccination rates across various population segments and thus driving the market growth. The continuous growth of the vaccine pipeline, with new vaccines targeting diseases like malaria, Zika, and cancer, helps meet unmet medical needs and addresses emerging infectious diseases, further expanding market opportunities. Moreover, the aging U.S. population is significantly augmenting the demand for vaccines like shingles, pneumococcal, and influenza vaccines, as older individuals are more vulnerable to such infections. According to the National Institute on Aging (NIA) in 2020, the U.S. population aged 65 and older is expected to grow from 54 million in 2019 to 94.7 million by 2060. This demographic shift is expected to drive demand for vaccines targeting older adults, including vaccines for shingles and pneumonia. Furthermore, increased awareness and education about the benefits of vaccination, supported by public health campaigns, drive higher vaccination rates and encourage more individuals to get vaccinated against common preventable diseases. However, high costs associated with vaccine research, development, and manufacturing can limit the availability and affordability of vaccines, especially for emerging diseases or smaller market segments. Moreover, public skepticism about vaccine safety, fueled by misinformation and fear, poses a significant barrier to achieving high vaccination rates. On the contrary, breakthroughs in vaccine technology, such as the development of mRNA vaccines, nanoparticle-based vaccines, and adjuvant formulations, contribute to more effective and rapid vaccine production, which are expected to offer remunerative opportunities for the expansion of the market during the forecast period.

The U.S. vaccines market share is segmented on the basis of technology type, indication, and end user. On the basis of technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. Depending on indication, it is classified into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, and rubella; diphtheria, pertussis, and tetanus (DTP); polio; hepatitis; and other indications. By end user, it is segregated into pediatric, adults, and travelers.

Competition Analysis

The major players operating in the U.S. vaccines market include Bavarian Nordic, Merck & Co., Inc., Sanofi, Pfizer, Emergent Biosolutions, CSL, Moderna, Inc., Dynavax Technologies, Novavax, Inc., and GSK Plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Technology Type

Inactivated Vaccines
Toxoid Vaccines
Recombinant and Conjugate Vaccines
Live Attenuated Vaccines
Others

By Indication

Pneumococcal Disease
Influenza
Human Papilloma Virus
Meningococcal Disease
Rotavirus
Varicella
Measles, Mumps, and Rubella
Diphtheria, Pertussis, and Tetanus (DTP)
Polio
Hepatitis
Other Indications

By End User

Pediatric
Adults
Travelers

Key Market Players:

Bavarian Nordic
Merck & Co., Inc.
Sanofi
Pfizer
Emergent Biosolutions
CSL
Moderna, Inc.
Dynavax Technologies
Novavax, Inc.
GSK plc.

Product Code: A325351

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: U.S. VACCINES MARKET, BY TECHNOLOGY TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Technology Type
4.2. Inactivated Vaccines
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
4.3. Toxoid Vaccines
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
4.4. Recombinant And Conjugate Vaccines
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
4.5. Live Attenuated Vaccines
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
4.6. Others
- 4.6.1. Key Market Trends, Growth Factors and Opportunities

CHAPTER 5: U.S. VACCINES MARKET, BY INDICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
5.2. Pneumococcal Disease
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
5.3. Influenza
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
5.4. Human Papilloma Virus
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
5.5. Meningococcal Disease
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
5.6. Rotavirus
- 5.6.1. Key Market Trends, Growth Factors and Opportunities
5.7. Varicella
- 5.7.1. Key Market Trends, Growth Factors and Opportunities
5.8. Measles, Mumps, And Rubella
- 5.8.1. Key Market Trends, Growth Factors and Opportunities
5.9. Diphtheria, Pertussis, And Tetanus (DTP)
- 5.9.1. Key Market Trends, Growth Factors and Opportunities
5.10. Polio
- 5.10.1. Key Market Trends, Growth Factors and Opportunities
5.11. Hepatitis
- 5.11.1. Key Market Trends, Growth Factors and Opportunities
5.12. Other Indications
- 5.12.1. Key Market Trends, Growth Factors and Opportunities

CHAPTER 6: U.S. VACCINES MARKET, BY END USER

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
6.2. Pediatric
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
6.3. Adults
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
6.4. Travelers
- 6.4.1. Key Market Trends, Growth Factors and Opportunities

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning,2023

CHAPTER 8: COMPANY PROFILES

8.1. Bavarian Nordic
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
8.2. Merck And Co., Inc.
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
8.3. Sanofi
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
8.4. Pfizer
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
8.5. Emergent Biosolutions
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
8.6. CSL
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
8.7. Moderna, Inc.
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
8.8. Dynavax Technologies
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
8.9. Novavax, Inc.
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
8.10. GSK Plc.
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments

TABLE 1. U.S. VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. U.S. VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 3. U.S. VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 4. BAVARIAN NORDIC: KEY EXECUTIVES
TABLE 5. BAVARIAN NORDIC: COMPANY SNAPSHOT
TABLE 6. BAVARIAN NORDIC: OPERATING SEGMENTS
TABLE 7. BAVARIAN NORDIC: PRODUCT PORTFOLIO
TABLE 8. BAVARIAN NORDIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 9. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 10. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 11. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 12. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 13. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14. SANOFI: KEY EXECUTIVES
TABLE 15. SANOFI: COMPANY SNAPSHOT
TABLE 16. SANOFI: OPERATING SEGMENTS
TABLE 17. SANOFI: PRODUCT PORTFOLIO
TABLE 18. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 19. PFIZER: KEY EXECUTIVES
TABLE 20. PFIZER: COMPANY SNAPSHOT
TABLE 21. PFIZER: OPERATING SEGMENTS
TABLE 22. PFIZER: PRODUCT PORTFOLIO
TABLE 23. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24. EMERGENT BIOSOLUTIONS: KEY EXECUTIVES
TABLE 25. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
TABLE 26. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS
TABLE 27. EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO
TABLE 28. EMERGENT BIOSOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 29. CSL: KEY EXECUTIVES
TABLE 30. CSL: COMPANY SNAPSHOT
TABLE 31. CSL: OPERATING SEGMENTS
TABLE 32. CSL: PRODUCT PORTFOLIO
TABLE 33. CSL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34. MODERNA, INC.: KEY EXECUTIVES
TABLE 35. MODERNA, INC.: COMPANY SNAPSHOT
TABLE 36. MODERNA, INC.: OPERATING SEGMENTS
TABLE 37. MODERNA, INC.: PRODUCT PORTFOLIO
TABLE 38. MODERNA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 39. DYNAVAX TECHNOLOGIES: KEY EXECUTIVES
TABLE 40. DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 41. DYNAVAX TECHNOLOGIES: OPERATING SEGMENTS
TABLE 42. DYNAVAX TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 43. DYNAVAX TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 44. NOVAVAX, INC.: KEY EXECUTIVES
TABLE 45. NOVAVAX, INC.: COMPANY SNAPSHOT
TABLE 46. NOVAVAX, INC.: OPERATING SEGMENTS
TABLE 47. NOVAVAX, INC.: PRODUCT PORTFOLIO
TABLE 48. NOVAVAX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 49. GSK PLC.: KEY EXECUTIVES
TABLE 50. GSK PLC.: COMPANY SNAPSHOT
TABLE 51. GSK PLC.: OPERATING SEGMENTS
TABLE 52. GSK PLC.: PRODUCT PORTFOLIO
TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

FIGURE 1. U.S. VACCINES MARKET,2024 - 2033
FIGURE 2. SEGMENTATION OF U.S. VACCINES MARKET,2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN U.S. VACCINES MARKET,2024 - 2033
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: U.S. VACCINES MARKET
FIGURE 10. U.S. VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION)
FIGURE 11. U.S. VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION)
FIGURE 12. U.S. VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: U.S. VACCINES MARKET
FIGURE 19. TOP PLAYER POSITIONING,2023
FIGURE 20. BAVARIAN NORDIC: NET SALES, 2022-2024 ($BILLION)
FIGURE 21. BAVARIAN NORDIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 22. BAVARIAN NORDIC: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 23. MERCK AND CO., INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 24. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 25. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 26. SANOFI: NET SALES, 2022-2024 ($BILLION)
FIGURE 27. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 29. PFIZER: NET SALES, 2022-2024 ($BILLION)
FIGURE 30. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. PFIZER: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 32. EMERGENT BIOSOLUTIONS: NET SALES, 2022-2024 ($BILLION)
FIGURE 33. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 35. CSL: NET SALES, 2022-2024 ($BILLION)
FIGURE 36. CSL: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. CSL: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 38. MODERNA, INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 39. MODERNA, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. MODERNA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 41. DYNAVAX TECHNOLOGIES: NET SALES, 2022-2024 ($BILLION)
FIGURE 42. DYNAVAX TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. DYNAVAX TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 44. NOVAVAX, INC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 45. NOVAVAX, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. NOVAVAX, INC.: REVENUE SHARE, BY REGION, 2024 (%)
FIGURE 47. GSK PLC.: NET SALES, 2022-2024 ($BILLION)
FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2024 (%)